Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Xiang Wang

TitleAssociate Professor
InstitutionUniversity of Colorado Boulder
DepartmentChemistry
Phone303/492-6266

    Collapse Research 
    Collapse research activities and funding
    R41CA291231     (FORD, HEIDE L.)Aug 15, 2024 - Jul 31, 2025
    NIH
    Preclinical Studies to Develop an Eya2 Tyr Phosphatase Inhibitor as a Novel Medulloblastoma Therapeutic
    Role: Co-Principal Investigator

    R33AI121365     (DETWEILER, CORRELLA)Dec 1, 2015 - Nov 30, 2021
    NIH
    A Novel Screen for Antibacterials that Are Non-Toxic to Mammals
    Role: Co-Principal Investigator

    R33AI121581     (WANG, XIANG)Dec 1, 2015 - Nov 30, 2021
    NIH
    Development of Novel Resistance-Modifying Agents for MRSA
    Role: Principal Investigator

    R21AI121365     (DETWEILER, CORRELLA)Dec 1, 2015 - Nov 30, 2017
    NIH
    A Novel Screen for Antibacterials that Are Non-Toxic to Mammals
    Role: Co-Principal Investigator

    R21AI121581     (WANG, XIANG)Dec 1, 2015 - Nov 30, 2017
    NIH
    Development of Novel Resistance-Modifying Agents for MRSA
    Role: Principal Investigator

    R01GM098390     (WANG, XIANG)Aug 1, 2012 - Jul 31, 2018
    NIH
    Specific Chemical Probes for Histone Demethylases
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Harris SL, Dutta S, Liu N, Wollenberg T, Wang X. Extended structure-activity relationship studies of the [1,2,5]oxadiazolo[3,4-b]pyrazine-containing colistin adjuvants. Bioorg Med Chem Lett. 2025 Jan 01; 115:130008. PMID: 39481690.
      View in: PubMed
    2. Dutta S, Eyolfson S, Zhu Y, Gao Y, Wang X. Practical synthesis of isoindolines yields potent colistin potentiators for multidrug-resistant Acinetobacter baumannii. Org Biomol Chem. 2024 05 22; 22(20):4057-4061. PMID: 38716633.
      View in: PubMed
    3. Dutta S, Liu N, Gao Y, Beck L, Wang X. Structure-activity relationship studies of [1,2,5]oxadiazolo[3,4-b]pyrazine-containing polymyxin-selective resistance-modifying agents. Bioorg Med Chem Lett. 2022 09 15; 72:128878. PMID: 35788034.
      View in: PubMed
    4. Wang X, Chen J, Wang W, Jaunarajs A, Wang X. Tryptoline-based benzothiazoles re-sensitize MRSA to ß-lactam antibiotics. Bioorg Med Chem. 2019 11 01; 27(21):115095. PMID: 31521461.
      View in: PubMed
    5. He W, Griffiths BM, Wang W, Wang X. Diastereoselective synthesis and biological evaluation of enantiomerically pure tricyclic indolines. Org Biomol Chem. 2017 May 16; 15(19):4241-4245. PMID: 28466945.
      View in: PubMed
    6. Zhu Y, Cleaver L, Wang W, Podoll JD, Walls S, Jolly A, Wang X. Tetracyclic indolines as a novel class of ß-lactam-selective resistance-modifying agent for MRSA. Eur J Med Chem. 2017 Jan 05; 125:130-142. PMID: 27657810.
      View in: PubMed
    7. Xu W, Wang W, Wang X. Gold-Catalyzed Cyclization Leads to a Bridged Tetracyclic Indolenine that Represses ß-Lactam Resistance. Angew Chem Int Ed Engl. 2015 Aug 10; 54(33):9546-9. PMID: 26074499.
      View in: PubMed
    8. Wang W, Marholz LJ, Wang X. Novel Scaffolds of Cell-Active Histone Demethylase Inhibitors Identified from High-Throughput Screening. J Biomol Screen. 2015 Jul; 20(6):821-7. PMID: 25883088.
      View in: PubMed
    9. Michael Barbour P, Podoll JD, Marholz LJ, Wang X. Discovery and initial structure-activity relationships of N-benzyl tricyclic indolines as antibacterials for methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett. 2014 Dec 15; 24(24):5602-5605. PMID: 25466183.
      View in: PubMed
    10. Wang XA, Cianci CW, Yu KL, Combrink KD, Thuring JW, Zhang Y, Civiello RL, Kadow KF, Roach J, Li Z, Langley DR, Krystal M, Meanwell NA. Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorg Med Chem Lett. 2007 Aug 15; 17(16):4592-8. PMID: 17576060.
      View in: PubMed
    11. Yu KL, Wang XA, Civiello RL, Trehan AK, Pearce BC, Yin Z, Combrink KD, Gulgeze HB, Zhang Y, Kadow KF, Cianci CW, Clarke J, Genovesi EV, Medina I, Lamb L, Wyde PR, Krystal M, Meanwell NA. Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo. Bioorg Med Chem Lett. 2006 Mar 01; 16(5):1115-22. PMID: 16368233.
      View in: PubMed
    12. Yu KL, Zhang Y, Civiello RL, Trehan AK, Pearce BC, Yin Z, Combrink KD, Gulgeze HB, Wang XA, Kadow KF, Cianci CW, Krystal M, Meanwell NA. Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. Bioorg Med Chem Lett. 2004 Mar 08; 14(5):1133-7. PMID: 14980651.
      View in: PubMed
    Wang's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)